Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04516616 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 1 wordv5
  2. Trial status: Recruiting to Active, Not Recruitingv4 Show 6 more changesShow less
    • Enrollment target: estimated 82 to confirmed 85
    • Primary completion date changed from estimate of Oct 1, 2023 to Apr 30, 2023
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 2 of 3 entries
    • Site details revised
    • Collaborators: 9 to 10
  3. Primary completion date: Dec 1, 2021 to Oct 1, 2023v3 Show 4 more changesShow less
    • Enrollment target: 84 to 82
    • Study completion date: Sep 1, 2026 to Jul 1, 2028
    • Eligibility criteria revised
    • Secondary endpoints revised (3)
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2020 to Dec 1, 2020
    • Site details revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. This is an open-label, single-arm, multi-center clinical trial to evaluate whether PD-1 in combination with neoadjuvant chemotherapy will achieve better objective response rate.
Trial Details
NCT Number NCT04516616
Lead Sponsor Huazhong University of Science and Technology
Collaborators: Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Army Medical University, China, Peking University People's Hospital, Tianjin Medical University General Hospital, The Second Affiliated Hospital of Harbin Medical University, Chongqing University Cancer Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Conditions
(from sponsor)		 Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer
Related terms Uterine Cervical Neoplasms
Enrollment 85 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov